Association Between Hypnotics, Accidents, and Injuries: A Study Based on the Adverse Drug Event Reporting Database in Japan

被引：0

作者：

Sogawa, Rintaro ^{[1
]}

Hatano, Masakazu ^{[2
]}

Nishimura, Fumi ^{[1
]}

Nishi, Junya ^{[1
]}

Matsuoka, Ayaka ^{[3
]}

Shinada, Kota ^{[3
]}

Yamada, Haruna ^{[4
]}

Tateishi, Hiroshi ^{[5
]}

Mizoguchi, Yoshito ^{[5
]}

Monji, Akira ^{[6
]}

Shimanoe, Chisato ^{[1
]}

机构：

[1] Saga Univ Hosp, Dept Pharm, 5-1-1 Nabeshima, Saga 8498501, Japan

[2] Fujita Hlth Univ, Sch Med, Dept Pharmacotherapeut & Informat, Toyoake, Japan

[3] Saga Univ Hosp, Dept Emergency & Crit Care Med, Nabeshima, Japan

[4] Saga Univ, Inst Nursing, Fac Med, Nabeshima, Japan

[5] Saga Univ, Fac Med, Dept Psychiat, Nabeshima, Japan

[6] Wakahisa Hosp, Wakahisa, Japan

来源：

IN VIVO | 2025年 / 39卷 / 01期

关键词：

Accident; adverse drug event; hypnotics; injury; HIGHWAY DRIVING PERFORMANCE; ZOPICLONE; 7.5; MG; METAANALYSIS; MEDICATION; FALLS; RISK; PLACEBO;

D O I：

10.21873/invivo.13846

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: The use of hypnotic drugs can lead to accidents and injuries. However, few reports have shown their association with these events after adjusting for many concomitant medications. This study aimed to determine whether the use of hypnotic drugs was associated with accidents and injuries. Patients and Methods: Using the Japanese Adverse Event Reporting Database, 772,387 reports published between September 2023 and April 2004 were analyzed. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) for accidents and injuries associated with each hypnotic drug were calculated after adjusting for potential confounders. Results: Of the total, 12,484 reports indicated association of hypnotic drugs with accidents and injuries. The use of each hypnotic drug was associated with accidents, injuries, and other adverse events. However, a multivariate analysis adjusted for age, sex, reporting year, and concomitant medications showed a considerable decrease in ROR for melatonin receptor agonists (adjusted ROR=1.26; 95%CI=1.03-1.55) and dual orexin receptor antagonists (DORAs) (adjusted ROR=1.04; 95%CI=0.86-1.25). Particularly in DORAs, a loss of signal for accidents and injuries was observed. Conclusion: The risk of accidents and injuries may vary with hypnotic drug use; however, DORAs may be less frequently associated with these events. The results of this study provide useful information for the selection of hypnotic drugs.

引用

页码：433 / 439

页数：7

共 50 条

[31] Adverse event profile differences between rituximab and ocrelizumab: findings from the fda adverse event reporting database
Caldito, N. Gonzalez
Shirani, A.
Salter, A.
Stuve, O.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 257 - 257
[32] Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database
Kato, Hideo
Shiraishi, Chihiro
Hagihara, Mao
Mikamo, Hiroshige
Iwamoto, Takuya
SCIENTIFIC REPORTS, 2024, 14 (01):
[33] Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database
Yang, Qing
Wang, Junyan
Wang, Menghuan
Zhang, Shuyu
He, Qin-Qin
BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):
[34] Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
Nagai, Junko
Ishikawa, Yoichi
PLOS ONE, 2021, 16 (12):
[35] Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
Zheng, Yi
Guo, Xiaojing
Chen, Chenxin
Chi, Lijie
Guo, Zhijian
Liang, Jizhou
Wei, Lianhui
Chen, Xiao
Ye, Xiaofei
He, Jia
PHARMACEUTICALS, 2023, 16 (01)
[36] Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database
Wang, Bojing
Huang, Shu
Li, Shiqi
Deng, Yaqi
Li, Ziyan
Wang, Yizhou
Shi, Xiaomin
Zhang, Wei
Shi, Lei
Wang, Xiaohong
Tang, Xiaowei
FRONTIERS IN PHARMACOLOGY, 2025, 15
[37] A Real-World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
Hai, Le
Wu, Jiaojiao
Xie, Yingying
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (10)
[38] Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system
Okada, Naoto
Yanagi, Tomoyuki
Sasaki, Takaaki
Tamura, Miho
Ozaki, Masakazu
Saisyo, Atsuyuki
Kitahara, Takashi
INTERNATIONAL JOURNAL OF CANCER, 2025, 156 (02) : 293 - 298
[39] Adverse drug events of denosumab: Data-mining based on the United States Food and Drug Administration Adverse Event Reporting System database
Liu, Shaohua
Jiang, Wangyan
Guo, Jieru
Zhou, Xinrong
Liu, Zhelong
JOURNAL OF RESEARCH IN PHARMACY, 2024, 28 (04): : 1220 - 1230
[40] Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study
Wu, Jingying
Wu, Jianru
Tang, Biyu
Wang, Xinru
Wei, Fenfang
Zhang, Yi
Li, Limin
Li, Hongqiao
Wang, Bei
Wu, Wenyu
Hong, Xiang
FRONTIERS IN PHARMACOLOGY, 2024, 15

← 1 2 3 4 5 →